High-definition reconstruction of clonal composition in cancer

Cell Reports

Volumn 7, Issue 5, 2014, Pages 1740-1752

  Fischer, Andrej ^a   Vázquez García, Ignacio ^a,b   Illingworth, Christopher J R ^c   Mustonen, Ville ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; ARTICLE; BREAST CANCER; CANCER GROWTH; CHRONIC LYMPHATIC LEUKEMIA; CLONAL EVOLUTION; CLONE HIGH DEFINITION; CONTROLLED STUDY; DISEASE COURSE; GENE DOSAGE; GENETIC HETEROGENEITY; GERMLINE MUTATION; HETEROZYGOTE; HIGH THROUGHPUT SEQUENCING; HUMAN; PRIORITY JOURNAL; QUALITY CONTROL; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SYSTEM ANALYSIS; CANCER GENETICS; CLONAL VARIATION; CLONEHD ALGORITHM; COPY NUMBER VARIATION; DNA SEQUENCE; FUZZY SYSTEM; GENE FREQUENCY; GENETIC ALGORITHM; GENOTYPE; MALIGNANT NEOPLASTIC DISEASE; PATIENT MONITORING;

EID: 84902315822     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.04.055     Document Type: Article

References (51)

1. Abecasis G.R., Auton A., Brooks L.D., DePristo M.A., Durbin R.M., Handsaker R.E., Kang H.M., Marth G.T., McVean G.A. An integrated map of genetic variation from 1,092 human genomes. Nature 2012, 491:56-65. 1000 Genomes Project Consortium.
2. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A.J.R., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg Å., Børresen-Dale A.-L., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421. Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer ConsortiumICGC Breast Cancer Consortium, ICGC MMML-Seq ConsortiumICGC MMML-Seq Consortium, ICGC PedBrainICGC PedBrain.
3. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Campbell P.J., Stratton M.R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013, 3:246-259.
4. Alsolami R., Knight S.J., Schuh A. Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?. Per. Med. 2013, 10:361-376.
5. Aparicio S., Caldas C. The implications of clonal genome evolution for cancer medicine. N.Engl. J. Med. 2013, 368:842-851.
6. Bedard P.L., Hansen A.R., Ratain M.J., Siu L.L. Tumour heterogeneity in the clinic. Nature 2013, 501:355-364.
7. Bolli N., Avet-Loiseau H., Wedge D.C., Van Loo P., Alexandrov L.B., Martincorena I., Dawson K.J., Iorio F., Nik-Zainal S., Bignell G.R., et al. Heterogeneity of genomic architecture and evolution in multiple myeloma. Nat. Commun. 2013, 5:1-13.
8. Bozic I., Allen B., Nowak M.A. Dynamics of targeted cancer therapy. Trends Mol. Med. 2012, 18:311-316.
9. Bryant J.M., Harris S.R., Parkhill J., Dawson R., Diacon A.H., van Helden P., Pym A., Mahayiddin A.A., Chuchottaworn C., Sanne I.M., et al. Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Lancet Respir. Med. 2013, 1:786-792.
10. Burrell R.A., McGranahan N., Bartek J., Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501:338-345.
11. Carter S.L., Cibulskis K., Helman E., McKenna A., Shen H., Zack T., Laird P.W., Onofrio R.C., Winckler W., Weir B.A., et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 2012, 30:413-421.
12. Chen M., Gunel M., Zhao H. SomatiCA: identifying, characterizing and quantifying somatic copy number aberrations from cancer genome sequencing data. PLoS ONE 2013, 8:e78143.
13. Fischer A., Illingworth C.J., Campbell P.J., Mustonen V. EMu: probabilistic inference of mutational processes and their localization in the cancer genome. Genome Biol. 2013, 14:R39.
14. Garraway L.A., Lander E.S. Lessons from the cancer genome. Cell 2013, 153:17-37.
15. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N.Engl. J. Med. 2012, 366:883-892.
16. Gonzalez-Perez A., Mustonen V., Reva B., Ritchie G.R.S., Creixell P., Karchin R., Vazquez M., Fink J.L., Kassahn K.S., Pearson J.V., et al. Computational approaches to identify functional genetic variants in cancer genomes. Nat. Methods 2013, 10:723-729. International Cancer Genome Consortium Mutation Pathways and Consequences Subgroup of the Bioinformatics Analyses Working Group.
17. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481:306-313.
18. Greenman C.D., Bignell G., Butler A., Edkins S., Hinton J., Beare D., Swamy S., Santarius T., Chen L., Widaa S., et al. PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data. Biostatistics 2010, 11:164-175.
19. Ha G., Roth A., Lai D., Bashashati A., Ding J., Goya R., Giuliany R., Rosner J., Oloumi A., Shumansky K., et al. Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer. Genome Res. 2012, 22:1995-2007.
20. Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A., Kadel S., Moll I., Nagore E., Hemminki K., et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013, 339:959-961.
21. Huang F.W., Hodis E., Xu M.J., Kryukov G.V., Chin L., Garraway L.A. Highly recurrent TERT promoter mutations in human melanoma. Science 2013, 339:957-959.
22. Jiao W., Vembu S., Deshwar A.G., Stein L., Morris Q. Inferring clonal evolution of tumors from single nucleotide somatic mutations. BMC Bioinformatics 2014, 15:35.
23. Kalman R.E. A new approach to linear filtering and prediction problems. J.Basic Eng. 1960, 82:35-45.
24. Landau D.A., Carter S.L., Stojanov P., McKenna A., Stevenson K., Lawrence M.S., Sougnez C., Stewart C., Sivachenko A., Wang L., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013, 152:714-726.
25. Lang G.I., Rice D.P., Hickman M.J., Sodergren E., Weinstock G.M., Botstein D., Desai M.M. Pervasive genetic hitchhiking and clonal interference in forty evolving yeast populations. Nature 2013, 500:571-574.
26. Larson N.B., Fridley B.L. PurBayes: estimating tumor cellularity and subclonality in next-generation sequencing data. Bioinformatics 2013, 29:1888-1889.
27. Lawrence M.S., Stojanov P., Polak P., Kryukov G.V., Cibulskis K., Sivachenko A., Carter S.L., Stewart C., Mermel C.H., Roberts S.A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499:214-218.
28. Li A., Liu Z., Lezon-Geyda K., Sarkar S., Lannin D., Schulz V., Krop I., Winer E., Harris L., Tuck D. GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays. Nucleic Acids Res. 2011, 39:4928-4941.
29. Lieberman T.D., Flett K.B., Yelin I., Martin T.R., McAdam A.J., Priebe G.P., Kishony R. Genetic variation of a bacterial pathogen within individuals with cystic fibrosis provides a record of selective pressures. Nat. Genet. 2014, 46:82-87.
30. Liu Z., Li A., Schulz V., Chen M., Tuck D. MixHMM: inferring copy number variation and allelic imbalance using SNP arrays and tumor samples mixed with stromal cells. PLoS ONE 2010, 5:e10909.
31. McLaren W., Pritchard B., Rios D., Chen Y., Flicek P., Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 2010, 26:2069-2070.
32. Mosén-Ansorena D., Aransay A.M., Rodríguez-Ezpeleta N. Comparison of methods to detect copy number alterations in cancer using simulated and real genotyping data. BMC Bioinformatics 2012, 13:192.
33. Navin N., Kendall J., Troge J., Andrews P., Rodgers L., McIndoo J., Cook K., Stepansky A., Levy D., Esposito D., et al. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472:90-94.
34. Nik-Zainal S., Alexandrov L.B., Wedge D.C., Van Loo P., Greenman C.D., Raine K., Jones D., Hinton J., Marshall J., Stebbings L.A., et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012, 149:979-993. Breast Cancer Working Group of the International Cancer Genome Consortium.
35. Nik-Zainal S., Van Loo P., Wedge D.C., Alexandrov L.B., Greenman C.D., Lau K.W., Raine K., Jones D., Marshall J., Ramakrishna M., et al. The life history of 21 breast cancers. Cell 2012, 149:994-1007. Breast Cancer Working Group of the International Cancer Genome Consortium.
36. Oesper L., Mahmoody A., Raphael B.J. THetA: inferring intra-tumor heterogeneity from high-throughput DNA sequencing data. Genome Biol. 2013, 14:R80.
37. Potter N.E., Ermini L., Papaemmanuil E., Cazzaniga G., Vijayaraghavan G., Titley I., Ford A., Campbell P., Kearney L., Greaves M. Single-cell mutational profiling and clonal phylogeny in cancer. Genome Res. 2013, 23:2115-2125.
38. Rasmussen M., Sundström M., Göransson Kultima H., Botling J., Micke P., Birgisson H., Glimelius B., Isaksson A. Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity. Genome Biol. 2011, 12:R108.
39. Roth A., Khattra J., Yap D., Wan A., Laks E., Biele J., Ha G., Aparicio S., Bouchard-CÔté A., Shah S.P. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 2014, 11:396-398.
40. Schuh A., Becq J., Humphray S., Alexa A., Burns A., Clifford R., Feller S.M., Grocock R., Henderson S., Khrebtukova I., et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 2012, 120:4191-4196.
41. Shah S.P., Morin R.D., Khattra J., Prentice L., Pugh T., Burleigh A., Delaney A., Gelmon K., Guliany R., Senz J., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813.
42. Shapiro E., Biezuner T., Linnarsson S. Single-cell sequencing-based technologies will revolutionize whole-organism science. Nat. Rev. Genet. 2013, 14:618-630.
43. Song S., Nones K., Miller D., Harliwong I., Kassahn K.S., Pinese M., Pajic M., Gill A.J., Johns A.L., Anderson M., et al. qpure: A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS ONE 2012, 7:e45835.
44. Stratton M.R., Campbell P.J., Futreal P.A. The cancer genome. Nature 2009, 458:719-724.
45. Su X., Zhang L., Zhang J., Meric-Bernstam F., Weinstein J.N. PurityEst: estimating purity of human tumor samples using next-generation sequencing data. Bioinformatics 2012, 28:2265-2266.
46. Sun W., Wright F.A., Tang Z., Nordgard S.H., Van Loo P., Yu T., Kristensen V.N., Perou C.M. Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res. 2009, 37:5365-5377.
47. Van Loo P., Nordgard S.H., Lingjærde O.C., Russnes H.G., Rye I.H., Sun W., Weigman V.J., Marynen P., Zetterberg A., Naume B., et al. Allele-specific copy number analysis of tumors. Proc. Natl. Acad. Sci. USA 2010, 107:16910-16915.
48. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
49. Wargo A.R., Huijben S., de Roode J.C., Shepherd J., Read A.F. Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Proc. Natl. Acad. Sci. USA 2007, 104:19914-19919.
50. Wheeler D.A., Wang L. From human genome to cancer genome: the first decade. Genome Res. 2013, 23:1054-1062.
51. Yau C., Mouradov D., Jorissen R.N., Colella S., Mirza G., Steers G., Harris A., Ragoussis J., Sieber O., Holmes C.C. A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biol. 2010, 11:R92.